Logo for Iovance Biotherapeutics Inc

Iovance Biotherapeutics Investor Relations Material

Latest events

Logo for Iovance Biotherapeutics Inc

AGM 2024

Iovance Biotherapeutics
Logo for Iovance Biotherapeutics

AGM 2024

11 Jun, 2024
Logo for Iovance Biotherapeutics

Status Update

31 May, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies

Latest reports from Iovance Biotherapeutics Inc

Access all reports
Iovance Biotherapeutics (NASDAQ: IOVE) is a clinical-stage biotechnology company focused on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. Our lead candidate, Poziotinib, is an orally administered small molecule inhibitor that targets the ABL kinase family with broad spectrum kinase inhibitory activity including sensitivity to low plasma concentrations of inhibitors.